Nebenwirkungen · Imlygic
Imlygic 106 plaque forming units (PFU)/mL solution for injection Imlygic 108 plaque forming units (PFU)/mL solution for injection · Abschnitt 4.8 · PDF-Seite 9
HOS-220102 · Präparat HOS-216539
The most commonly reported adverse reactions (≥ 25%) in Imlygic-treated patients were fatigue (50.3%), chills (48.6%), pyrexia (42.8%), nausea (35.6%), influenza-like illness (30.5%), and injection site pain (27.7%). Overall, 98% of these adverse reactions reported were mild or moderate in severity. The most common grade 3 or higher adverse reaction was cellulitis (2.1%) (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-06T11:25:00Z · SHA-256 29b9626c83b5b3c819e8c60552ff83b355a7f2cd0eb94cf809da6fac4931003d · Passage f00b3e14f5e1cbfc83f507ed6ef9bc232477eb0020be3a2edd283bf6d4d08a7f · Zeichen 305–697 im Abschnitt